Payal Kapur

16.5k total citations
236 papers, 6.2k citations indexed

About

Payal Kapur is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Payal Kapur has authored 236 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 127 papers in Pulmonary and Respiratory Medicine, 99 papers in Molecular Biology and 69 papers in Surgery. Recurrent topics in Payal Kapur's work include Renal cell carcinoma treatment (80 papers), Renal and related cancers (51 papers) and Bladder and Urothelial Cancer Treatments (39 papers). Payal Kapur is often cited by papers focused on Renal cell carcinoma treatment (80 papers), Renal and related cancers (51 papers) and Bladder and Urothelial Cancer Treatments (39 papers). Payal Kapur collaborates with scholars based in United States, China and Austria. Payal Kapur's co-authors include James Brugarolas, Dinesh Rakheja, Yair Lotan, Alana Christie, Iván Pedrosa, Jer‐Tsong Hsieh, Vitaly Margulis, Mai P. Hoang, Aditya Bagrodia and Mengxiao Yu and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Angewandte Chemie International Edition.

In The Last Decade

Payal Kapur

224 papers receiving 6.1k citations

Peers

Countries citing papers authored by Payal Kapur

Since Specialization

Citations

This map shows the geographic impact of Payal Kapur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Payal Kapur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Payal Kapur more than expected).

Fields of papers citing papers by Payal Kapur

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Payal Kapur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Payal Kapur. The network helps show where Payal Kapur may publish in the future.

Co-authorship network of co-authors of Payal Kapur

This figure shows the co-authorship network connecting the top 25 collaborators of Payal Kapur. A scholar is included among the top collaborators of Payal Kapur based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Payal Kapur. Payal Kapur is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluating Therapeutic Efficacy of the Vascular Disrupting Agent OXi8007 Against Kidney Cancer in Mice 2025 ·Cancers ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Hans J. Hammers, Payal Kapur, (unknown), (unknown), Tianyuan Wang, (unknown), Mary Lynn Trawick, Kevin G. Pinney, Ralph P. Mason	2
2	Determinants of late metastases in renal cell carcinoma 2025 ·JNCI Journal of the National Cancer Institute ·Payal Kapur, Hua Zhong, Alana Christie, Haitao Xu, Qi Cai, Ellen Araj, David Kim, (unknown), Vanina Toffessi Tcheuyap, Colleen T. Ball, David D. Thiel, Alexander S. Parker, Samuel O. Antwi, Bradley C. Leibovich, Zora Modrušan, John C. Cheville, James Brugarolas	0
3	Retroperitoneal Sarcomatoid Yolk Sac Tumor in a Chemotherapy-Naive Patient With Testicular Postpubertal Type Teratoma: A Rare Case Report With Emphasis on Molecular Features 2024 ·International Journal of Surgical Pathology ·Bo Zhang, Payal Kapur, Prasad Koduru, Liwei Jia	2
4	Unconventional mechanism of action and resistance to rapalogs in renal cancer 2024 ·Proceedings of the National Academy of Sciences ·Juan Yang, Ramesh Butti, (unknown), Vanina Toffessi Tcheuyap, (unknown), My-Linh T. Nguyen, Christina Stevens, Alana Christie, Akhilesh Mishra, Yuanqing Ma, Jiwoong Kim, Robert T. Abraham, Payal Kapur, Robert E. Hammer, James Brugarolas	6
5	Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer 2023 ·European Urology ·Raquibul Hannan, Mark F. McLaughlin, Laurentiu M. Pop, Iván Pedrosa, Payal Kapur, Aurélie Garant, Chul Ahn, Alana Christie, James Zhu, Tao Wang, (unknown), (unknown), Solomon L. Woldu, Vitaly Margulis, Jeffrey Gahan, James Brugarolas, Robert Timmerman, Jeffrey A. Cadeddu	27
6	Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting 2023 ·Cancers ·Payal Kapur, James Brugarolas, Kiril Trpkov	13
7	Intratumoral Resolution of Driver Gene Mutation Heterogeneity in Renal Cancer Using Deep Learning 2022 ·Cancer Research ·(unknown), (unknown), (unknown), Alana Christie, (unknown), Vitaly Margulis, Dinesh Rakheja, John C. Cheville, Bradley C. Leibovich, Alexander S. Parker, James Brugarolas, Payal Kapur, Satwik Rajaram	21
8	ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma 2022 ·Clinical Cancer Research ·Aditi Mulgaonkar, Roy Elias, Layton Woolford, (unknown), Kien Nham, Payal Kapur, Alana Christie, Vanina Toffessi Tcheuyap, Nirmish Singla, I. Alex Bowman, Christina Stevens, Guiyang Hao, James Brugarolas, Xiankai Sun	10
9	Cell Competition Shapes Metastatic Latency and Relapse 2022 ·Cancer Discovery ·(unknown), Huocong Huang, Pravat Kumar Parida, Lan He, (unknown), (unknown), Payal Kapur, James Brugarolas, Rolf A. Brekken, Srinivas Malladi	13
10	Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney 2021 ·Modern Pathology ·Payal Kapur, (unknown), Hua Zhong, (unknown), Midori Mitui, Spencer Barnes, Qinbo Zhou, (unknown), (unknown), Venkat S. Malladi, Dinesh Rakheja, Iván Pedrosa, Lin Xu, Lisa N. Kinch, James Brugarolas	42
11	Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus—Safety Lead-in Results of a Phase 2 Trial 2021 ·International Journal of Radiation OncologyBiologyPhysics ·Vitaly Margulis, Yuval Freifeld, Laurentiu M. Pop, (unknown), Payal Kapur, Iván Pedrosa, Alana Christie, Osama Mohamad, (unknown), Nirmish Singla, Michael A. Wait, Aditya Bagrodia, Solomon L. Woldu, Jeffrey Gahan, James Brugarolas, Robert Timmerman, Raquibul Hannan	43
12	Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma 2020 ·Journal for ImmunoTherapy of Cancer ·Viral Patel, Roy Elias, (unknown), William Schwartzman, Alana Christie, Qi Cai, Venkat S. Malladi, Payal Kapur, Miguél Vázquez, Renée M. McKay, Iván Pedrosa, Raquibul Hannan, Hans J. Hammers, James Brugarolas	24
13	Summary From the First Kidney Cancer Research Summit, September 12–13, 2019: A Focus on Translational Research 2020 ·JNCI Journal of the National Cancer Institute ·Toni K. Choueiri, Michael B. Atkins, Ziad Bakouny, Maria I. Carlo, Charles G. Drake, Eric Jonasch, Payal Kapur, Bryan Lewis, W. Marston Linehan, Michael J. Mitchell, Sumanta K. Pal, (unknown), (unknown), W. Kimryn Rathmell, Brian I. Rini, Sabina Signoretti, Nizar M. Tannir, Robert G. Uzzo, Christopher G. Wood, Hans J. Hammers	15
14	Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation 2019 ·Clinical Cancer Research ·Eun-Jin Yun, (unknown), Andrew Dang, (unknown), Jiaming Guo, Wei‐Min Chen, Allison Joyce, Nathan Kim, Payal Kapur, James Brugarolas, Kaijie Wu, Dalin He, Chih‐Ho Lai, Ho Lin, Debabrata Saha, Seung Tae Baek, Benjamin P.C. Chen, Jer‐Tsong Hsieh	22
15	EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors 2018 ·Molecular Cancer Therapeutics ·Kenneth Chen, (unknown), Abhay A. Shukla, Emily K. Stroup, (unknown), (unknown), (unknown), Kiyoshi Yamaguchi, Payal Kapur, A. Lindsay Frazier, Lawrence Lum, Leendert H. J. Looijenga, Theodore W. Laetsch, Dinesh Rakheja, James F. Amatruda	11
16	Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade 2017 ·Cancer Discovery ·(unknown), (unknown), Alana Christie, Tiffani McKenzie, Nicholas C. Wolff, N. Quyen, Ananth J. Madhuranthakam, Iván Pedrosa, Tao Wang, Anwesha Dey, Meinrad Busslinger, Xian‐Jin Xie, Robert E. Hammer, Renée M. McKay, Payal Kapur, James Brugarolas	110
17	PBRM1 loss is a late event during the development of cholangiocarcinoma 2017 ·Histopathology ·Claudio Luchini, Scott Robertson, Seung‐Mo Hong, Matthäus Felsenstein, Robert A. Anders, Antonio Pea, Alessia Nottegar, Nicola Veronese, Jin He, Matthew J. Weiss, Paola Capelli, Aldo Scarpa, Pedram Argani, Payal Kapur, Laura D. Wood	23
18	A primary melanoma and its asynchronous metastasis highlight the role of BRAF, CDKN2A, and TERT 2014 ·Journal of Cutaneous Pathology ·Gregory A. Hosler, Teresa Davoli, İlgen Mender, (unknown), Jaehyuk Choi, Payal Kapur, Jerry W. Shay, Richard C. Wang	10
19	Atypical and malignant hidradenomas: a histological and immunohistochemical study 2009 ·Modern Pathology ·Rosalynn M. Nazarian, Payal Kapur, Dinesh Rakheja, Adriano Piris, Lyn M. Duncan, Martín C. Mihm, Mai P. Hoang	53
20	Computer tomography of the brain in Hamilton. 1975 ·PubMed ·M. Banna, (unknown), Payal Kapur, John T. Groves	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact